首页 > 最新文献

Clinical Microbiology and Infection最新文献

英文 中文
Detection of Borrelia burgdorferi sensu lato by proteomics: a complementary diagnosis tool on erythema migrans biopsies. 通过蛋白质组学检测包柔氏菌:偏头痛红斑活检的辅助诊断工具。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.014
Paola Cantero, Laurence Ehret-Sabatier, Cédric Lenormand, Yves Hansmann, Erik Sauleau, Laurence Zilliox, Benoit Westermann, Benoit Jaulhac, Didier Mutter, Cathy Barthel, Pauline Perdu-Alloy, Martin Martinot, Dan Lipsker, Nathalie Boulanger

Objectives: We have developed targeted proteomics in the context of Lyme borreliosis as a new direct diagnostic tool for detecting Borrelia proteins in the skin of patients with erythema migrans. If satisfactory, this proteomic technique could be used in addition to culture and/or PCR for disseminated infections, where Borrelia detection is essential to demonstrate active infection. In these infections, diagnosis is indirect and relies mainly on serology.

Methods: We recruited 46 patients with Lyme borreliosis and 11 controls and collected two skin biopsies from each patient. One biopsy was used for B. burgdorferi sensu lato PCR and culture and the other one was for targeted mass-spectrometry based proteomics. Six markers of infection were selected for proteomics: OspC, flagellin, enolase, lipoprotein gi|365823350, DpbA, and GAPDH.

Results: Culturing Borrelia from the biopsies increased the sensitivity of the methods. Among the patients included for analysis, 61% (28 patients), 61% (28), and 46% (21) were detected as positive, by proteomics, PCR, and culture respectively. PCR and proteomics were complementary. OspC and flagellin were the most frequently detected protein markers of infection by proteomics, which in some patients, detected up to 9 peptides for the flagellin.

Conclusions: It is possible to identify bacterial makers from the skin by proteomics. Our approach can be used to diagnose tick-borne diseases such as Lyme borreliosis.

Trial registration: ClinicalTrials.gov Identifier: NCT02414789.

目的:我们在莱姆包虫病的背景下开发了靶向蛋白质组学,作为一种新的直接诊断工具,用于检测迁延性红斑患者皮肤中的包柔氏菌蛋白质。如果效果令人满意,这种蛋白质组学技术可与培养和/或 PCR 技术一起用于播散性感染,在播散性感染中,检测包柔氏病菌是证明活动性感染的关键。在这些感染中,诊断是间接的,主要依赖血清学:我们招募了 46 名莱姆包虫病患者和 11 名对照组患者,并为每名患者采集了两份皮肤活检样本。方法:我们招募了 46 名莱姆包虫病患者和 11 名对照组患者,并为每名患者采集了两份皮肤活检样本。一份活检样本用于 B. burgdorferi sensu lato PCR 和培养,另一份活检样本用于基于质谱的靶向蛋白质组学研究。蛋白质组学选择了六个感染标记物:OspC、鞭毛蛋白、烯醇化酶、脂蛋白gi|365823350、DpbA和GAPDH:结果:从活检组织中培养鲍曼不动杆菌提高了方法的灵敏度。在纳入分析的患者中,通过蛋白质组学、PCR 和培养,分别有 61%(28 人)、61%(28 人)和 46%(21 人)被检测为阳性。PCR 和蛋白质组学是互补的。OspC和鞭毛蛋白是蛋白质组学最常检测到的感染蛋白质标记物,在一些患者中,鞭毛蛋白最多可检测到9个肽段:结论:通过蛋白质组学可以识别皮肤中的细菌制造者。我们的方法可用于诊断蜱传疾病,如莱姆包虫病:试验注册:ClinicalTrials.gov Identifier:NCT02414789。
{"title":"Detection of Borrelia burgdorferi sensu lato by proteomics: a complementary diagnosis tool on erythema migrans biopsies.","authors":"Paola Cantero, Laurence Ehret-Sabatier, Cédric Lenormand, Yves Hansmann, Erik Sauleau, Laurence Zilliox, Benoit Westermann, Benoit Jaulhac, Didier Mutter, Cathy Barthel, Pauline Perdu-Alloy, Martin Martinot, Dan Lipsker, Nathalie Boulanger","doi":"10.1016/j.cmi.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.014","url":null,"abstract":"<p><strong>Objectives: </strong>We have developed targeted proteomics in the context of Lyme borreliosis as a new direct diagnostic tool for detecting Borrelia proteins in the skin of patients with erythema migrans. If satisfactory, this proteomic technique could be used in addition to culture and/or PCR for disseminated infections, where Borrelia detection is essential to demonstrate active infection. In these infections, diagnosis is indirect and relies mainly on serology.</p><p><strong>Methods: </strong>We recruited 46 patients with Lyme borreliosis and 11 controls and collected two skin biopsies from each patient. One biopsy was used for B. burgdorferi sensu lato PCR and culture and the other one was for targeted mass-spectrometry based proteomics. Six markers of infection were selected for proteomics: OspC, flagellin, enolase, lipoprotein gi|365823350, DpbA, and GAPDH.</p><p><strong>Results: </strong>Culturing Borrelia from the biopsies increased the sensitivity of the methods. Among the patients included for analysis, 61% (28 patients), 61% (28), and 46% (21) were detected as positive, by proteomics, PCR, and culture respectively. PCR and proteomics were complementary. OspC and flagellin were the most frequently detected protein markers of infection by proteomics, which in some patients, detected up to 9 peptides for the flagellin.</p><p><strong>Conclusions: </strong>It is possible to identify bacterial makers from the skin by proteomics. Our approach can be used to diagnose tick-borne diseases such as Lyme borreliosis.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02414789.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: 'Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study' by Walt et al. 关于Walt 等人撰写的 "一项多队列研究中对 SARS-CoV-2 感染后循环病毒抗原的测量"。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.018
Guangting Zeng
{"title":"Re: 'Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study' by Walt et al.","authors":"Guangting Zeng","doi":"10.1016/j.cmi.2024.10.018","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.018","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants: a COVI-PREG prospective cohort study. 与未暴露的婴儿相比,子宫内暴露于 SARS-CoV-2 或 mRNA COVID-19 疫苗的婴儿的神经发育结果:COVI-PREG 前瞻性队列研究。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.019
Guillaume Favre, Rebecca L Bromley, Matthew Bluett-Duncan, Emeline Maisonneuve, Léo Pomar, Charlotte Daire, Anda-Petronela Radan, Luigi Raio, Daniel Surbek, Carolin Blume, Stylianos Kalimeris, Yoann Madec, Juliane Schneider, Myriam Bickle Graz, Ursula Winterfeld, Alice Panchaud, David Baud

Objectives: Data are lacking regarding the long-term consequences of SARS-CoV-2 and COVID-19 mRNA vaccine on infants exposed in utero. We aimed to evaluate the neurodevelopment of infants exposed prenatally to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy at 12 months after birth.

Methods: Infants born from mothers exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy, or unexposed to either the virus or the vaccine were enrolled from 2021 to 2023. Infants with prenatal exposure to the virus or vaccine were compared to infants without prenatal exposure to the virus and/or vaccine. Parents received a neurodevelopmental questionnaire (ASQ-3) at 12 months after birth assessing 5 subdomains: communication, gross motor, fine motor, problem solving and personal social development. A low score was defined as <2 standard deviations below the normative mean in at least one of the subdomains.

Results: A total of 330 infants were included (76 in the SARS-CoV-2 group; 153 in the mRNA-COVID-19 vaccine group; 101 in the reference group). In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine were not associated with an increased risk of a low score for at least one subdomain compared to the reference group. The crude odds ratios were 1.16 (95% confidence interval [CI] 0.59-2.28) and 1.04 (95% CI 0.58-1.86), respectively. Results remained consistent in the multivariate analysis, showing no increased risk of a low score for at least one subdomain for infants exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine, compared to the reference group. The adjusted odds ratios were 1.74 (95% CI 0.76-3.99) and 0.76 (95% CI 0.39-1.49), respectively.

Conclusion: In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one ASQ-3 subdomain at 12 months after birth. Additional studies are needed to confirm our results, especially longer-term evaluation of infant development.

目的:目前尚缺乏有关 SARS-CoV-2 和 COVID-19 mRNA 疫苗对宫内暴露婴儿的长期影响的数据。我们的目的是评估产前接种 SARS-CoV-2 或 mRNA-COVID-19 疫苗的婴儿在出生后 12 个月的神经发育情况:方法: 2021年至2023年期间,对母亲在怀孕期间接触过SARS-CoV-2或mRNA-COVID-19疫苗,或未接触过病毒或疫苗的婴儿进行了登记。产前接触过病毒或疫苗的婴儿与产前未接触过病毒和/或疫苗的婴儿进行了比较。父母在婴儿出生后 12 个月时会收到一份神经发育问卷 (ASQ-3),评估 5 个子领域:沟通、粗大运动、精细运动、解决问题和个人社交发展。结果:共纳入 330 名婴儿(SARS-CoV-2 组 76 名;mRNA-COVID-19 疫苗组 153 名;参照组 101 名)。与参照组相比,宫内接触 SARS-CoV-2 或 mRNA-COVID-19 疫苗与至少一个子域的低分风险增加无关。粗略的几率比分别为 1.16(95% 置信区间 [CI]:0.59-2.28)和 1.04(95% 置信区间 [CI]:0.58-1.86)。多变量分析的结果仍然一致,与参照组相比,接种过 SARS-CoV-2 或 mRNA-COVID-19 疫苗的婴儿至少在一个子域中得分低的风险没有增加。调整后的几率比分别为 1.74(95% CI 0.76-3.99)和 0.76(95% CI 0.39-1.49):结论:宫内接种SARS-CoV-2或mRNA-COVID-19疫苗与出生后12个月时至少一个ASQ-3子域得分低的风险增加无关。需要进行更多的研究来证实我们的结果,特别是对婴儿发育进行更长期的评估。
{"title":"Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants: a COVI-PREG prospective cohort study.","authors":"Guillaume Favre, Rebecca L Bromley, Matthew Bluett-Duncan, Emeline Maisonneuve, Léo Pomar, Charlotte Daire, Anda-Petronela Radan, Luigi Raio, Daniel Surbek, Carolin Blume, Stylianos Kalimeris, Yoann Madec, Juliane Schneider, Myriam Bickle Graz, Ursula Winterfeld, Alice Panchaud, David Baud","doi":"10.1016/j.cmi.2024.10.019","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.019","url":null,"abstract":"<p><strong>Objectives: </strong>Data are lacking regarding the long-term consequences of SARS-CoV-2 and COVID-19 mRNA vaccine on infants exposed in utero. We aimed to evaluate the neurodevelopment of infants exposed prenatally to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy at 12 months after birth.</p><p><strong>Methods: </strong>Infants born from mothers exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy, or unexposed to either the virus or the vaccine were enrolled from 2021 to 2023. Infants with prenatal exposure to the virus or vaccine were compared to infants without prenatal exposure to the virus and/or vaccine. Parents received a neurodevelopmental questionnaire (ASQ-3) at 12 months after birth assessing 5 subdomains: communication, gross motor, fine motor, problem solving and personal social development. A low score was defined as <2 standard deviations below the normative mean in at least one of the subdomains.</p><p><strong>Results: </strong>A total of 330 infants were included (76 in the SARS-CoV-2 group; 153 in the mRNA-COVID-19 vaccine group; 101 in the reference group). In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine were not associated with an increased risk of a low score for at least one subdomain compared to the reference group. The crude odds ratios were 1.16 (95% confidence interval [CI] 0.59-2.28) and 1.04 (95% CI 0.58-1.86), respectively. Results remained consistent in the multivariate analysis, showing no increased risk of a low score for at least one subdomain for infants exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine, compared to the reference group. The adjusted odds ratios were 1.74 (95% CI 0.76-3.99) and 0.76 (95% CI 0.39-1.49), respectively.</p><p><strong>Conclusion: </strong>In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one ASQ-3 subdomain at 12 months after birth. Additional studies are needed to confirm our results, especially longer-term evaluation of infant development.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infections in immunocompromised hosts: progress made and challenges ahead. 免疫力低下宿主的感染:取得的进展和面临的挑战。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.017
Joseph Sassine, Chrysanthi Skevaki, Roy F Chemaly
{"title":"Infections in immunocompromised hosts: progress made and challenges ahead.","authors":"Joseph Sassine, Chrysanthi Skevaki, Roy F Chemaly","doi":"10.1016/j.cmi.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.017","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates. 舒巴坦-杜鲁巴坦对产生 NDM 的大肠埃希菌(包括头孢克肟和阿曲南类阿维菌素耐药分离株)具有强效体外活性。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.012
Christophe Le Terrier, Patrice Nordmann, Adam Delaval, Laurent Poirel
{"title":"Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates.","authors":"Christophe Le Terrier, Patrice Nordmann, Adam Delaval, Laurent Poirel","doi":"10.1016/j.cmi.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.012","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"HANCEK" Infective Endocarditis: A Case for Including Neisseria elongata in the HACEK Group. "HACEK "感染性心内膜炎:将细长奈瑟菌纳入 HACEK 组的案例。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.015
Brandon J Webb, Mark A Fisher, Nick Tinker
{"title":"\"HANCEK\" Infective Endocarditis: A Case for Including Neisseria elongata in the HACEK Group.","authors":"Brandon J Webb, Mark A Fisher, Nick Tinker","doi":"10.1016/j.cmi.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.015","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial. 延长输注β-内酰胺类抗生素治疗血液病患者发热性中性粒细胞减少症的疗效(BEATLE):一项随机、多中心、开放标签、优势临床试验。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.006
Julia Laporte-Amargos, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Raul Rigo-Bonnin, Marta Ulldemolins, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina Garcia-Vidal, Natàlia Pallarès, Cristian Tebé, Carme Muñoz, Fe Tubau, Ariadna Padullés, Ana-Maria Sureda, Jordi Carratalà, Carlota Gudiol

Objectives: The efficacy of extended infusions (EI) of β-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of β-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia.

Methods: We performed a randomised, open-label, superiority clinical trial of patients with febrile neutropenia at four Spanish university hospitals. Patients undergoing haematopoietic stem cell transplantation or with acute leukaemia receiving chemotherapy who required empirical antibiotic treatment for febrile neutropenia were randomly assigned (1:1) to receive EI of β-lactam or II after a first dose in bolus. The choice of antipseudomonal β-lactam was left to the discretion of the attending physician. The primary endpoint was treatment success at day 5, defined as defervescence without modifying the antibiotic treatment. Secondary endpoints included adverse events, attainment of the pharmacokinetic/pharmacodynamic target of 50, 75 and 100%ƒuT>MIC, and 30-day mortality.

Results: Between November 19, 2019 and June 22, 2022, 295 patients we screened for eligibility, of whom 150 were randomly assigned to receive EI (n=77) or II (n=73) of the antipseudomonal β-lactam of choice. In the intention-to-treat analysis, treatment success at day 5 was achieved in 39/77 patients (50.6%) receiving EI versus 46/73 patients (63.0%) receiving II (risk difference -12.4%; 95% confidence interval, -29.4 to 4.7, p=0.17). The pharmacokinetic/pharmacodynamic targets of 75 and 100% ƒuT>MIC for empirical treatment were achieved more frequently in the EI group. No statistically-significant differences were found between groups in terms of adverse events or 30-day mortality.

Conclusions: Our findings do not support the routine use of empirical EI of β-lactams in febrile neutropenia. Further studies should consider the clinical heterogeneity of febrile neutropenia and focus on patients with sepsis/septic shock and microbiologically documented infections, particularly those with infections caused by microorganisms less susceptible to β-lactams.

目的:延长输注(EI)β-内酰胺类抗生素对发热性中性粒细胞减少症的疗效尚不明确。我们评估了在治疗发热性中性粒细胞减少症时,延长输注β-内酰胺类抗生素是否比间歇输注(II)更有效:我们在四家西班牙大学医院对发热性中性粒细胞减少症患者进行了随机、开放标签、优效性临床试验。接受造血干细胞移植或接受化疗的急性白血病患者因发热性中性粒细胞减少症而需要经验性抗生素治疗时,我们将其随机分配(1:1),在首剂栓剂后接受β-内酰胺类或II类抗生素的EI治疗。抗伪β-内酰胺的选择由主治医生决定。主要终点是第 5 天的治疗成功率,即在不改变抗生素治疗方案的情况下,患者病情得到缓解。次要终点包括不良事件、达到药代动力学/药效学目标 50、75 和 100%ƒuT>MIC 以及 30 天死亡率:在2019年11月19日至2022年6月22日期间,我们筛选了295名符合条件的患者,其中150人被随机分配接受EI(77人)或II(73人)抗假性β-内酰胺类药物的治疗。在意向治疗分析中,接受 EI 治疗的第 5 天成功率为 39/77 例患者(50.6%),而接受 II 治疗的第 5 天成功率为 46/73 例患者(63.0%)(风险差异为-12.4%;95% 置信区间为-29.4 至 4.7,P=0.17)。EI组患者更容易达到经验治疗的药代动力学/药效学目标,即75%和100% ƒuT>MIC。在不良事件或 30 天死亡率方面,各组之间没有发现显著的统计学差异:我们的研究结果不支持在发热性中性粒细胞减少症中常规使用经验性β-内酰胺类药物 EI。进一步的研究应考虑发热性中性粒细胞减少症的临床异质性,并重点关注败血症/败血症性休克和有微生物感染记录的患者,尤其是那些由对β-内酰胺类药物敏感性较低的微生物引起感染的患者。
{"title":"Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial.","authors":"Julia Laporte-Amargos, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Raul Rigo-Bonnin, Marta Ulldemolins, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina Garcia-Vidal, Natàlia Pallarès, Cristian Tebé, Carme Muñoz, Fe Tubau, Ariadna Padullés, Ana-Maria Sureda, Jordi Carratalà, Carlota Gudiol","doi":"10.1016/j.cmi.2024.10.006","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.006","url":null,"abstract":"<p><strong>Objectives: </strong>The efficacy of extended infusions (EI) of β-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of β-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia.</p><p><strong>Methods: </strong>We performed a randomised, open-label, superiority clinical trial of patients with febrile neutropenia at four Spanish university hospitals. Patients undergoing haematopoietic stem cell transplantation or with acute leukaemia receiving chemotherapy who required empirical antibiotic treatment for febrile neutropenia were randomly assigned (1:1) to receive EI of β-lactam or II after a first dose in bolus. The choice of antipseudomonal β-lactam was left to the discretion of the attending physician. The primary endpoint was treatment success at day 5, defined as defervescence without modifying the antibiotic treatment. Secondary endpoints included adverse events, attainment of the pharmacokinetic/pharmacodynamic target of 50, 75 and 100%ƒ<sub>u</sub>T<sub>>MIC</sub>, and 30-day mortality.</p><p><strong>Results: </strong>Between November 19, 2019 and June 22, 2022, 295 patients we screened for eligibility, of whom 150 were randomly assigned to receive EI (n=77) or II (n=73) of the antipseudomonal β-lactam of choice. In the intention-to-treat analysis, treatment success at day 5 was achieved in 39/77 patients (50.6%) receiving EI versus 46/73 patients (63.0%) receiving II (risk difference -12.4%; 95% confidence interval, -29.4 to 4.7, p=0.17). The pharmacokinetic/pharmacodynamic targets of 75 and 100% ƒ<sub>u</sub>T<sub>>MIC</sub> for empirical treatment were achieved more frequently in the EI group. No statistically-significant differences were found between groups in terms of adverse events or 30-day mortality.</p><p><strong>Conclusions: </strong>Our findings do not support the routine use of empirical EI of β-lactams in febrile neutropenia. Further studies should consider the clinical heterogeneity of febrile neutropenia and focus on patients with sepsis/septic shock and microbiologically documented infections, particularly those with infections caused by microorganisms less susceptible to β-lactams.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Why don't we talk about Tuberculosis stewardship?" "我们为什么不谈谈结核病管理?"
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.013
Niccolò Riccardi, Tommaso Matucci, Marco Falcone
{"title":"\"Why don't we talk about Tuberculosis stewardship?\"","authors":"Niccolò Riccardi, Tommaso Matucci, Marco Falcone","doi":"10.1016/j.cmi.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.013","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elucidating the role of internal migration in the spread of M. tuberculosis. 阐明国内迁移在结核杆菌传播中的作用。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.011
Kesia Esther Da Silva, Jason R Andrews
{"title":"Elucidating the role of internal migration in the spread of M. tuberculosis.","authors":"Kesia Esther Da Silva, Jason R Andrews","doi":"10.1016/j.cmi.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.011","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Candida auris MIC testing by EUCAST and CLSI broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant? 通过 EUCAST 和 CLSI 肉汤微量稀释及梯度扩散条进行的念珠菌 MIC 检测;对两性霉素 B 是否耐药?
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-17 DOI: 10.1016/j.cmi.2024.10.010
Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold

Objectives: Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing or adoption of a clinical breakpoint (BP) that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.

Methods: Forty C. auris strains from nine US states and ≥3 clades were included. Fourteen MIC data sets were generated using EUCAST E.Def 7.4, CLSI M27Ed4, Etest and MTS (Liofilchem) strip MICs. MICs ≤1 mg/L were classified as susceptible.

Results: EUCAST and CLSI amphotericin B MIC testing were robust across included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar GM-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest and MTS strip MICs correlated to the OD of drug-free control EUCAST wells suggesting that some isolates grew better than others and that this was associated with MIC.

Conclusions: The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggest the current breakpoint leads to random susceptibility classification.

目的:据报道,白色念珠菌对两性霉素 B 的耐药率差异很大。这可能反映了与临床相关的药敏性差异、检测技术问题或采用了将野生型群体一分为二的临床断点(BP)。我们使用共享的 C. auris 菌株库比较了参考方法和两种梯度扩散条:方法:纳入了来自美国九个州、≥3 个支系的 40 株 C. auris 菌株。使用 EUCAST E.Def 7.4、CLSI M27Ed4、Etest 和 MTS(Liofilchem)条带 MIC 生成 14 个 MIC 数据集。MIC≤1 mg/L 被归类为易感:结果:EUCAST和CLSI两性霉素B的MIC测试在各种方法变量中都很稳健。模态 MIC 为 1 毫克/升,呈单峰分布,范围较窄,GM-MIC 相似(0.745-1.072);但药敏性分类各不相同(0-28% 抗药)。梯度扩散带测试结果显示,8/9 个数据集的分布较宽且呈双峰分布。如果按照制造商的协议,在 Etest 方法中采用双重接种,则模态 MIC 增加到 2-4 mg/L,耐药率增加到 45-63%,而单次接种的耐药率为 25-30%。EUCAST、CLSI、Etest和MTS条带的MIC与无药对照EUCAST孔的OD相关,表明一些分离物比其他分离物生长得更好,这与MIC有关:结论:EUCAST 和 CLSI 的 MIC 结果接近一致,而条带测试则显示出更广泛的双峰分布,读者与读者之间以及中心与中心之间存在差异。我们的研究增加了人们对两性霉素 B 抗球虫商业 MIC 检测的担忧,并表明目前的断点会导致随机药敏性分类。
{"title":"Candida auris MIC testing by EUCAST and CLSI broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant?","authors":"Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold","doi":"10.1016/j.cmi.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.010","url":null,"abstract":"<p><strong>Objectives: </strong>Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing or adoption of a clinical breakpoint (BP) that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.</p><p><strong>Methods: </strong>Forty C. auris strains from nine US states and ≥3 clades were included. Fourteen MIC data sets were generated using EUCAST E.Def 7.4, CLSI M27Ed4, Etest and MTS (Liofilchem) strip MICs. MICs ≤1 mg/L were classified as susceptible.</p><p><strong>Results: </strong>EUCAST and CLSI amphotericin B MIC testing were robust across included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar GM-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest and MTS strip MICs correlated to the OD of drug-free control EUCAST wells suggesting that some isolates grew better than others and that this was associated with MIC.</p><p><strong>Conclusions: </strong>The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggest the current breakpoint leads to random susceptibility classification.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Microbiology and Infection
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1